Full-Time
CRM Specialist
Posted on 6/30/2025
Pattern Bioscience
51-200 employees
AI-driven rapid bacterial ID and AST
No salary listed
Pune, Maharashtra, India
In Person
This position is onsite in Pune, India.
 Growth & Marketing (1) |
|---|
- Advanced CRM tools proficiency (e.g., Klaviyo, Dot Digital, Mailchimp)
- Intermediate GA4 proficiency
- Basic Looker Studio proficiency
- Intermediate data analysis ability
- Basic Canva skills
- Bachelor’s degree in Marketing, Business, or related field
- Excellent analytical and problem-solving skills
- Detail oriented
- Effective planner
- Results Driven
- Strong collaboration and communication skills
- Develop and implement CRM campaigns
- Manage customer segmentation strategies
- Deploy CRM campaigns for multiple clients
- Continuously measure and optimise campaign performance
- Generate insights from data analysis
- Optimise CRM processes for efficiency and effectiveness
- Communicate clearly with clients to manage expectations and deliverables.
- Advanced CRM certifications preferred
Pattern Bioscience develops rapid clinical diagnostics that identify bacterial infections and determine antibiotic resistance. Its system uses single-cell analysis with AI pattern recognition to deliver definitive ID/AST results in about four hours. The product suite includes diagnostic devices, consumables, service contracts, and software for AI analysis. By speeding and improving accuracy, Pattern Bioscience aims to help hospitals reduce inappropriate antibiotic use and combat antibiotic resistance.
Company Size
51-200
Company Stage
Series D
Total Funding
$91.6M
Headquarters
Austin, Texas
Founded
2016
Simplify's Take
What believers are saying
- $43M Series D funding from AMR Action Fund supports FDA 510(k) submission.
- $40.9M BARDA contract accelerates pneumonia and bacteremia panel development.
- Over 1,000 samples enrolled in multi-center trial for Q3 regulatory push.
What critics are saying
- Accelerate Diagnostics' PhenoVue captures market with FDA-cleared 3-hour AST.
- BioFire's FilmArray dominates ICU syndromic testing, sidelining single-pathogen focus.
- Clinical trial failure by mid-2026 exhausts Series D runway, halting launch.
What makes Pattern Bioscience unique
- Digital CultureTM enables culture-free phenotypic ID/AST in four hours.
- Single-cell analysis captures all resistance mechanisms unlike genotypic tests.
- Pneumonia ID/AST Panel targets critically ill patients with FDA Breakthrough Designation.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Pattern Bioscience who can refer or advise you
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Unlimited Paid Time Off
Paid Holidays
401(k) Company Match
401(k) Retirement Plan
Health Savings Account/Flexible Spending Account
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 2%2 year growth
↓ -1%Pattern Bioscience has raised $43 million in Series D funding, led by AMR Action Fund, Illumina Ventures, and Omnimed Capital. The funds will support a US multi-center clinical trial and regulatory submission for their Pneumonia ID/AST Panel, which has FDA Breakthrough Device Designation and is backed by a BARDA contract worth up to $40.9 million. Latham & Watkins LLP represented Pattern Bioscience in the transaction.
To quickly develop effective treatments for drug-resistant bacterial infections, Pattern is a leader in the application of single-cell microbiology.
Pattern Bioscience secures $28.7 million in Series C financing to accelerate development of first-of-its-kind infectious disease diagnostic platform
Pattern Bioscience, an Austin, TX-based company which specializes in rapid diagnosis and antibiotic susceptibility testing (AST) for bacterial infections, raised $28.7M in Series C funding.
Including the Series C round, Pattern has now raised $68 million to date, the company said in a statement.